The BMS Symposium is hosted by Professor Sergey Pronin and sponsored by Bristol Myers Squibb. It will feature lectures by Sarah Reisman of the California Institute of Technology and Natalie Holmberg Douglas of Bristol Myers Squibb.

2:00 PM: Introduction by Sergey Pronin

2:10 PM: Natalie Holmberg Douglas: “Discovery of BMS-986458, an Orally Bioavailable BCL6 Ligand-Directed Degrader”

3:10 PM: Reception Break

3:30 PM: Sarah Reisman: “Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire”

Learn more about Sarah Reisman's work on the Reisman Group website. Learn more about Natalie Holmberg Douglas' work on her ResearchGate page. 

Abstract for “Discovery of BMS-986458, an Orally Bioavailable BCL6 Ligand-Directed Degrader” - Natalie Holmberg Douglas (BMS): 

Targeted protein degradation (TPD) is an emerging therapeutic approach that harnesses the cell's own disposal machinery to destroy disease-driving proteins, including many long considered "undruggable." One such target is BCL6, a transcription factor that drives tumor growth and treatment resistance in B-cell lymphomas like DLBCL and follicular lymphoma. Bristol Myers Squibb has disclosed two BCL6 degraders: BMS-986458, an orally available candidate now in phase I/II clinical trials, and BCL6-760, a tool compound for preclinical studies. This talk will cover the discovery of BMS-986458 and the challenge of advancing these large, "beyond rule of 5" degraders into the clinic.